{
  "abstract": "Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of Neisseria gonorrhoeae (n = 322) collected in the United States in 2020–2022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC50/90 values of 0.12 µg/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.",
  "abstract_shown": true,
  "affiliations": [
    "Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., Waltham, Massachusetts, USA",
    "IHMA, Inc., Schaumburg, Illinois, USA",
    "Global Antibiotic R&D Partnership, Geneva, Switzerland"
  ],
  "article_type": "brief report",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sarah M. McLeod",
      "orcid": "0009-0003-7827-794X"
    },
    {
      "affs": [
        0
      ],
      "name": "Samir H. Moussa",
      "orcid": "0000-0001-5348-596X"
    },
    {
      "affs": [
        1
      ],
      "name": "Meredith Hackel",
      "orcid": "0000-0003-3339-2701"
    },
    {
      "affs": [
        2
      ],
      "name": "Carmen Au"
    },
    {
      "affs": [
        2
      ],
      "name": "Pierre Daram"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4k7yxnr46fcfx.bib",
  "cited_by": 0,
  "doi": "10.1128/aac.00527-26",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13712928/",
  "id": "4k7yxnr46fcfx",
  "issns": [
    "0066-4804",
    "1098-6596"
  ],
  "landing_url": "https://doi.org/10.1128/aac.00527-26",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Epidemiology and Surveillance"
    ],
    [
      "openalex",
      "2404|Reproductive tract infections research"
    ]
  ],
  "openalex": "W7172340630",
  "pdf_url": "https://journals.asm.org/doi/pdf/10.1128/aac.00527-26?download=true",
  "pmcid": "PMC13712928",
  "pmid": "42545106",
  "published": "2026-08-03",
  "publisher": "American Society for Microbiology (ASM)",
  "ris": "https://research.draconitic.com/paper/4k7yxnr46fcfx.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:23:25Z",
      "native_id": "PMC13712928",
      "source": "pmc",
      "url": "https://doi.org/10.1128/aac.00527-26"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2404|Reproductive tract infections research",
      "subfield": "microbiology"
    }
  ],
  "title": "In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022",
  "title_text": "In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:23:25Z",
  "url": "https://research.draconitic.com/paper/4k7yxnr46fcfx",
  "venue": "Antimicrobial Agents and Chemotherapy",
  "versions": []
}